491 related articles for article (PubMed ID: 29175677)
1. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib: A Review in Metastatic Colorectal Cancer.
Dhillon S
Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer.
Xue WS; Men SY; Liu W; Liu RH
Medicine (Baltimore); 2018 Oct; 97(40):e12635. PubMed ID: 30290640
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
Anticancer Res; 2017 Nov; 37(11):5925-5934. PubMed ID: 29061771
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
15. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
16. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
17. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
Mitchell J; Khoukaz T; McNeal D; Brent L
Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
19. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
20. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
García-Alfonso P; Feliú J; García-Carbonero R; Grávalos C; Guillén-Ponce C; Sastre J; García-Foncillas J
Clin Transl Oncol; 2016 Nov; 18(11):1072-1081. PubMed ID: 27037815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
